Benzinga | Apr 1, 2021 06:45AM EDT

HC Wainwright & Co. Maintains Buy on AzurRx BioPharma, Lowers Price Target to $2.5

HC Wainwright & Co. analyst Yi Chen maintains AzurRx BioPharma (NASDAQ:AZRX) with a Buy and lowers the price target from $3.5 to $2.5.